INTRODUCTION
Induction of labour is carried out in over 20% of pregnancies on an average in developed countries. 1 Indicated to be advantageous for both the mother & baby. Decrease perinatal morbidity and mortality. 2, 3 Induction between 37-41 weeks has the potential to improve neonatal outcomes.
Methods of Induction of Labour: [A]
Medical: Use of Mifepristone 4 , Prostaglandin, 5, 6 Synthetic oxytocin preparations, natural induction, Relaxin. 7 [B] Mechanical: "Membrane sweep"/"stretch and sweep", Artificial rupture of the membranes.
Indication for Induction of labour: Post-term pregnancy, Intrauterine fetal growth retardation, Medical disorders of pregnancy (e.g. she has pre-eclampsia), Premature rupture of the membranes, premature termination of the pregnancy (abortion), scheduling concerns, fetal death in uterus, twin pregnancy continuing beyond 38 weeks.
Mifepristone /RU-(486), a new class of pharmacological agents (antiprogestins) have been developed to antagonize the action of progesterone. Of these, mifepristone (also called RU 486) is best known. It is a 19 nor-steroid which has greater affinity for progesterone receptors than does progesterone itself. It blocks the action of progesterone at the cellular level.
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Pharmacokinetics of Mifepristone: It is characterized by rapid absorption, long half-life of 25 to 30 hours. 8 Key metabolites also has high affinity to progesterone receptors. Mifepristone is a potential as a method of inducing labour in late pregnancy through its actions in antagonizing progesterone, thus increasing uterine contractility and by increasing the sensitivity of the uterus to the actions of prostaglandins.
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Aim and Objectives  To study the effectiveness and safety of mifepristone for cervical ripening for Induction of labour in term pregnancies.  To compare the effect mifepristone in study group with a control group of same size.  To observe the improvement in cervical score as compared to control group.  To view the final outcome of the interventional group and compare it with the control group.  To study the occurrence of neonatal complications in study and compare it to control group.
METHODS
A randomized case control study comparing effect of mifepristone for cervical ripening in labour induction, with placebo/no treatment. Place of study: Acharya Vinoba Bhave Rural Hospital, Sawangi (Meghe), Wardha.
Inclusion Criteria: Patient giving consent for the study, singleton pregnancy, cases included were of gestational at term after 37 completed weeks, they had normal latest sonography without any complications.
Exclusion Criteria: Patient not giving consent for the study, multiple pregnancies, any obstetric cause for contraindication for induction of labour (previous scar on uterus, any coagulation failure, placenta previa). Patients with any other associated medical condition or disease which contraindicates the use of mifepristone example: Adrenal insufficiency.
The patients in the study group received one tablet mifepristone 200mg per oral stat at induction into the trial. Then the patient was reviewed for bishop score after 24 hours and 48 hours. Any progression of associated conditions was also noted.
Subgroup analyses will be limited to the primary outcomes:
 Vaginal delivery achieved within 24-48 hours  Requirement of augmentation  Uterine hyper stimulation with fetal heart rate (FHR) changes  Instrumental delivery or Caesarean section Secondary outcomes:
 Cervix unfavourable/unchanged after 48 hours.  Serious neonatal morbidity or perinatal death (e.g.
seizures, birth asphyxia defined by trial lists, neonatal encephalopathy, disability in childhood).  Serious maternal morbidity or mortality (e.g. uterine rupture, admission to intensive care unit, septicaemia).
RESULTS
Out 50 study group women (Total n=100), 34 (68%) were primigravida and 16 (32%) were multiparas, whereas out of 50 women in control group 26 (52%) were primigravida and 24 (48 %) were multigravida. The patients were stratified by Bishop Score at entry for further analysis. 
Maternal complications in relation study and control group
Cases of failed induction were omitted in calculation of complications. The majority did not have any major complications in either of the group like sepsis, pyrexia and PPH. Just few minor genital tract injuries but the difference was not significant statistically in the study group. Li L, Gao W, Chen S 5 did a study at Beijing Tian Tan Hospital, Capital University of Medicine on Labour induction in women at term with mifepristone and misoprostol. Results of their study women who were given mifepristone: the cervical length was 1-3 cm shorter and Bishop score was 4-5 higher than those before treatment. The cervical ripening ratio was 100.00%. Incidence of the onset of labor was 93.00%. Incidence of vaginally delivery was 80.88% after misoprostol was given for augmentation. Similarly in our study vaginal delivery rate was 76% and rate of augmentation was 26%. 
DISCUSSION

Mode of delivery
